Viome Introduces CancerDetect® Pancreatic for Early Detection of Pancreatic Cancer

Viome Launches Revolutionary CancerDetect® Pancreatic Test

Viome PRO, a clinical division of Viome Life Sciences, has officially launched its latest advancement, the CancerDetect® Pancreatic, a groundbreaking blood test designed for the early detection of pancreatic cancer. This new diagnostic tool targets pancreatic ductal adenocarcinoma by assessing enzyme activity linked to the disease.

In a recent blinded validation study conducted by Viome, the test demonstrated remarkable effectiveness, identifying 86% of stage I and II pancreatic cancers with a specificity of 90% when compared to healthy controls. These statistics not only highlight the potential of this test but also underscore the urgency of early detection, especially since pancreatic cancer is regarded as one of the most lethal cancers.

The CancerDetect® Pancreatic test is accessible through a simple blood draw, ordered by healthcare providers. The samples are processed in Viome's accredited CLIA-certified laboratory, ensuring reliable results for patients. This innovative testing approach is specifically geared towards individuals aged 50 years or older, as they represent a significant demographic at elevated risk for pancreatic cancer.

Among those at higher risk include individuals diagnosed with type 2 diabetes, those possessing specific genetic predispositions, smokers, and heavy drinkers. Dr. Brad Younggren, President of Viome PRO, emphasizes the critical nature of early surveillance for pancreatic cancer, reflecting on his experiences witnessing advanced cases emerge in patients already aware of their risk factors. He states, "Surveillance with early-stage detection is incredibly important in pancreatic cancer, and it is where every existing test underperforms. A best-in-class diagnostic test for early disease detection will allow for much better early surveillance in higher-risk patients."

Pancreatic cancer ranks as the third leading cause of cancer-related mortality in the United States, with projections estimating over 67,000 new diagnoses this year alone, resulting in approximately 52,740 deaths. Alarmingly, only 14% of cases are caught while the cancer remains localized, significantly minimizing the chances of successful treatment and increasing mortality rates. The median five-year relative survival rate plummets to just 3.1% once the cancer has progressed to distant stages, reinforcing the dire need for improved diagnostic methods.

Among the noteworthy features of the CancerDetect® Pancreatic test is its unique mechanism. Unlike traditional approaches that rely heavily on existing biomarkers or imaging techniques, this test measures enzyme activity associated with the tumor's invasive behavior, which can appear early in the cancer's development. This enables clinicians to identify signals even when tumors are still small, thereby amplifying the detectability of target enzymes present in minuscule quantities.

Momo Vuyisich, Co-Founder and Chief Science Officer at Viome Life Sciences, elucidates the advantages of focusing on enzyme activity, stating, "Enzyme activity is a functional readout of what a tumor is doing, and it is there early. Pairing that specificity with the sensitivity the amplification gives us is when I knew this test was worth bringing to market."

Fountain Life, a company specializing in longevity and preventive health, is set to be the first to offer the CancerDetect® Pancreatic test to its members. With locations in various states including Texas and New York, Fountain Life is dedicated to providing advanced health services. Chief Medical Officer Dr. Dawn Mussallem notes, "Pancreatic cancer is one of the hardest cancers to find early, and for most people, we have no good way to look. CancerDetect Pancreatic gives our physicians one more signal for members at higher risk."

It is crucial to note that while CancerDetect® Pancreatic provides valuable insights, it is not a diagnostic tool on its own. Any positive result will necessitate further imaging and clinical evaluation, while a negative result does not completely exclude the possibility of pancreatic cancer.

Viome Life Sciences stands at the forefront of biological innovation since its foundation in 2016, committed to making chronic illnesses and cancers preventable by decoding individual health at a molecular level. The company’s development of this test aligns with its mission to leverage AI and sequencing technologies to facilitate the creation of innovative health solutions for both consumers and healthcare providers.

In summary, the introduction of the CancerDetect® Pancreatic test signifies a pivotal step in the fight against pancreatic cancer, representing hope for early detection and the possibility of improving patient outcomes significantly. As Viome continues to enhance its offerings, the medical community eagerly anticipates the impact of this innovative test on public health.